Protein That Helps Keep Breast Cancer Dormant Identified
Complete the form below to unlock access to ALL audio articles.
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light on the molecular basis underlying how the expression of certain genes facilitates the spread of metastatic lesions.
The research also identified a protein that is associated with lowered risk of relapse in the tumors it is expressed in, making it a possible starting point for treatments targeting relapsing cancers.
The time needed for breast cancer metastases (secondary lesions caused by cells that have escaped from the original tumor) to develop varies between patients, and little is known about the mechanisms that govern latency (the dormant state of cells that have already spread through the body).
The team has studied the most common kind of breast tumor--estrogen-positive (ER +) and accounting for 80% of breast cancer tumor cases--that is characterized by a long period of latency with no symptoms. The study has been published today in Nature Cell Biology.
MSK1, the protein that keeps tumor cells dormant
The team has identified the protein kinase MSK1 as a key regulator of dormant or latent metastases. Using clinical samples from patients, the scientists have confirmed that ER + breast cancer tumors that do not express MSK1 are associated with a risk of earlier relapse, while those that express this molecule will form metastases later.
The team then showed that suppressing MSK1 results in faster growing cancer cells that are more likely to migrate into other areas of the body.
"We are interested in understanding the mechanisms underlying metastasis and the time component of this process. Until now, little was known in preclinical models about the mechanisms that allow breast cancer cells to leave the latent state and even less is known in patients," explains Roger Gomis, head of the Growth Control and Cancer Metastasis Lab.
The researchers believe that in the future this discovery may benefit patients in two ways. Firstly, it will help to identify those with an imminent risk of relapse and to adjust the treatment for this prognosis. Secondly, attempts could be made to design a treatment to mimic the function of MSK1 kinase, with the aim to maintain metastatic lesions in a latent and asymptomatic state for as long as possible.
This article has been republished from materials provided by IRB Barcelona. Note: material may have been edited for length and content. For further information, please contact the cited source.
Reference: Gawrzak, S., Rinaldi, L., Gregorio, S., Arenas, E. J., Salvador, F., Urosevic, J., … Gomis, R. R. (2018). MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer. Nature Cell Biology, 1. https://doi.org/10.1038/s41556-017-0021-z
